GlassScriptPhysician profile
Lucy Min Joo
NPI 1669813804
$1,539.65
in general payments reported to CMS, 2019-2025
20 companies · $836 in 2025
The $836 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.11 · 2022: $15.00 · 2023: $73.10 · 2024: $601 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $326.86 | 2024-2025 | Conmed Hemostasis, Conmed Biliary, Conmed Dilation |
| Takeda Pharmaceuticals U.S.A., INC. | $196.29 | 2024-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $170.03 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Ipsen Biopharmaceuticals, INC | $168.37 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $118.16 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $105.94 | 2024 | |
| Aimmune Therapeutics, INC. | $97.83 | 2025 | Vowst, Zenpep |
| Abbvie INC. | $77.11 | 2024-2025 | |
| Celgene Corporation | $42.79 | 2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.94 | 2025 | Xifaxan |
| Exact Sciences Corporation | $34.03 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $26.55 | 2025 | Voquezna |
| Qol Medical, LLC | $23.41 | 2025 | Sucraid |
| Genzyme Corporation | $19.20 | 2025 | |
| Celltrion USA INC. | $17.67 | 2024 | Vegzelma |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $17.08 | 2025 | Sutab, Suflave |
| Mauna Kea Technologies, INC. | $15.30 | 2025 | |
| Erbe USA INC | $15.00 | 2022 | |
| Boston Scientific Corporation | $14.11 | 2019 | |
| Madrigal Pharmaceuticals | $13.98 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Joo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.